Global Anthelmintic Drugs Market Size study, by Drug Class (Benzimidazoles, Macrocyclic Lactones, Pyrazinoisoquinolones, Tetrahydropyrimidines, Others), by Infection Type (Cestode Infections, Nematode Infections, Trematode Infections, Mixed Infections), b

Global Anthelmintic Drugs Market Size study, by Drug Class (Benzimidazoles, Macrocyclic Lactones, Pyrazinoisoquinolones, Tetrahydropyrimidines, Others), by Infection Type (Cestode Infections, Nematode Infections, Trematode Infections, Mixed Infections), by Distribution Channel (Online Providers, Hospital Pharmacies, Drug Stores and Retail Pharmacies), and Regional Forecasts 2022-2032

The Global Anthelmintic Drugs Market size was valued at $1.05 billion in 2023 and anticipated to grow at a CAGR of 3.94% from 2024-2032. Anthelmintics are specialized drugs that target and eliminate parasitic worms, or helminths, from the body. These drugs work by either expelling the parasites or disrupting their metabolic processes, leading to their destruction. The increasing prevalence of helminth infections globally is a key driver for market growth. According to the World Health Organization (WHO), soil-transmitted helminth (STH) infections affect an estimated 1.5 billion people, which is approximately 24% of the world's population. These infections are especially prevalent in impoverished communities with limited access to safe water, sanitation, and hygiene, thereby amplifying the demand for anthelmintic drugs.

The growing awareness of preventive measures against helminth infections and the availability of generic drugs significantly contribute to the market expansion. Educational campaigns and public health initiatives play a crucial role in increasing awareness and encouraging proactive measures for the prevention and treatment of parasitic infections. The market dynamics are further influenced by the availability of generic medications, which provide cost-effective alternatives to branded drugs, thereby reducing treatment expenses. However, the affordability of these drugs remains a challenge, particularly in low-income regions where access to healthcare is limited. Moreover, the challenges posed by economic downturns and potential reductions in research funding, the demand for anthelmintic drugs is expected to remain robust due to the high prevalence of parasitic infections and the ongoing need for effective treatments.

The key regions considered for the Global Anthelmintic Drugs Market study include Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. In 2023, North America dominates the anthelmintic drugs market due to its advanced healthcare infrastructure, high awareness levels, and substantial investment in research and development. The region's strong presence of key pharmaceutical companies, coupled with significant government support for healthcare initiatives, further bolsters its leading position. The prevalence of helminthic infections, particularly in rural and underprivileged areas, drives the demand for effective treatments. Additionally, the increasing adoption of pets and livestock, which are common carriers of parasitic worms, fuels the need for anthelmintic drugs. Stringent regulatory frameworks ensure the availability of high-quality, safe, and effective medications. Furthermore, robust distribution networks and the presence of numerous veterinary and human health clinics facilitate easy access to these drugs. Thus, North America's dominance is attributed to its comprehensive approach to healthcare, encompassing advanced research, widespread awareness, and efficient delivery systems. Furthermore, the Asia-Pacific region is anticipated to be the fastest growing region during the forecast period 2024-2032.

Major market players included in this report are:

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co., Inc.

Bayer AG

Cipla Ltd.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited

Reese Pharmaceutical Company

Zydus Lifesciences Limited

Cadila Pharmaceuticals

Regulus

John Lee

Mediva

Intas Pharmaceuticals

Mankind Pharma Ltd

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Benzimidazoles

Macrocyclic Lactones

Pyrazinoisoquinolones

Tetrahydropyrimidines

Others

By Infection Type

Cestode Infections

Nematode Infections

Trematode Infections

Mixed Infections

By Distribution Channel

Online Providers

Hospital Pharmacies

Drug Stores and Retail Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.